Catalent, Inc. (NYSE:CTLT) Receives Average Rating of “Hold” from Brokerages

Catalent, Inc. (NYSE:CTLT) has earned an average rating of “Hold” from the eleven ratings firms that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and three have assigned a buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $55.65.

A number of research analysts have issued reports on CTLT shares. Barclays upped their target price on shares of Catalent from $47.00 to $63.00 and gave the company an “equal weight” rating in a research report on Friday, June 28th. StockNews.com initiated coverage on shares of Catalent in a research note on Thursday, August 1st. They set a “sell” rating on the stock. Finally, Royal Bank of Canada reissued a “sector perform” rating and set a $63.50 price objective on shares of Catalent in a research note on Thursday, July 11th.

Insider Activity

In other news, CEO Alessandro Maselli sold 9,088 shares of Catalent stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $58.76, for a total value of $534,010.88. Following the sale, the chief executive officer now directly owns 177,521 shares in the company, valued at $10,431,133.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, SVP Scott Gunther sold 666 shares of the firm’s stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $59.55, for a total value of $39,660.30. Following the completion of the transaction, the senior vice president now directly owns 39,635 shares of the company’s stock, valued at $2,360,264.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Alessandro Maselli sold 9,088 shares of the firm’s stock in a transaction on Monday, July 29th. The shares were sold at an average price of $58.76, for a total transaction of $534,010.88. Following the completion of the transaction, the chief executive officer now directly owns 177,521 shares of the company’s stock, valued at $10,431,133.96. The disclosure for this sale can be found here. Insiders have sold 14,810 shares of company stock worth $858,941 over the last ninety days. Insiders own 0.31% of the company’s stock.

Hedge Funds Weigh In On Catalent

Several hedge funds and other institutional investors have recently made changes to their positions in CTLT. Nomura Holdings Inc. boosted its position in Catalent by 149.4% during the fourth quarter. Nomura Holdings Inc. now owns 11,487,342 shares of the company’s stock worth $516,126,000 after purchasing an additional 6,881,914 shares during the period. Norges Bank bought a new position in Catalent during the fourth quarter worth $116,021,000. Capital World Investors boosted its position in Catalent by 6.1% during the fourth quarter. Capital World Investors now owns 19,079,994 shares of the company’s stock worth $857,264,000 after purchasing an additional 1,098,474 shares during the period. Magnetar Financial LLC bought a new position in Catalent during the first quarter worth $56,429,000. Finally, Cadian Capital Management LP boosted its position in Catalent by 14.3% during the fourth quarter. Cadian Capital Management LP now owns 6,064,384 shares of the company’s stock worth $272,473,000 after purchasing an additional 759,600 shares during the period.

Catalent Trading Down 0.8 %

Shares of Catalent stock opened at $59.12 on Tuesday. The firm has a market capitalization of $10.70 billion, a PE ratio of -9.69, a price-to-earnings-growth ratio of 2.47 and a beta of 1.16. The company has a debt-to-equity ratio of 1.37, a current ratio of 2.51 and a quick ratio of 1.77. The company’s fifty day moving average price is $56.66 and its two-hundred day moving average price is $56.12. Catalent has a 52-week low of $31.80 and a 52-week high of $60.20.

Catalent (NYSE:CTLT) last posted its earnings results on Wednesday, May 8th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of $0.21 by ($0.36). The firm had revenue of $1.07 billion during the quarter, compared to the consensus estimate of $1.11 billion. Catalent had a negative return on equity of 2.73% and a negative net margin of 26.61%. On average, analysts expect that Catalent will post -0.17 EPS for the current year.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.